Chemotherapy resistance is a major obstacle to the effective treatment of patients with gastric cancer (GC). Mounting evidence has indicated that the dysregulation of microRNAs (miRNAs) is associated with the sensitivity of cancer cells to chemotherapy. However, the mechanisms underlying miRNA-mediated chemoresistance in GC cells remain to be elucidated. The present study aimed to identify functional miRNAs that may regulate the sensitivity of human GC cells to cisplatin (DDP) treatment. miRNA microarray analysis was used to identify differentially expressed miRNAs between the human cisplatin-sensitive GC cell line SGC7901 and the corresponding cisplatin-resistant cell line SGC7901/DDP. miRNA (miR)-362-5p, which is associated with numerous types of tumors, was identified to be downregulated in the SGC7901/DDP cell line. However, the biological role of miR-362-5p in SGC7901/DDP cells remains to be explored. The expression level of miR-362-5p was demonstrated to be reduced in SGC7901/DDP cells compared with SGC7901 cells by reverse transcription-quantitative PCR. Upregulation of miR-362-5p significantly increased cisplatin sensitivity and cisplatin-induced apoptosis, whereas downregulation of miR-362-5p attenuated these effects. Databases predicted that suppressor of zeste 12 protein (SUZ12) may function as a target of miR-362-5p. In addition, the mRNA and protein expression levels of SUZ12 in SGC7901/DDP cells were significantly higher compared with SGC7901 cells and negatively associated with miR-362-5p expression. MTT and western blot analysis assays confirmed that knockdown of SUZ12 enhanced cisplatin sensitivity and decreased NF-κB/p65 protein levels in SGC7901/DDP cells. In addition, upregulation of miR-362-5p in SGC7901/DDP cells decreased the protein expression level of SUZ12, whereas downregulation of miR-362-5p increased the SUZ12 expression level. The results of the present study suggested that dysregulated miR-362-5p may target SUZ12 to promote the development of cisplatin resistance and attenuate cisplatin-induced apoptosis. Therefore, miR-362-5p upregulation combined with cisplatin treatment may serve as a promising therapeutic strategy for patients with cisplatin-resistant GC.
This paper presents interval type-2 fuzzy logic (IT2FL) controller applied on a direct torque controlled (DTC) permanent magnet synchronous motor (PMSM), using digital signal processing (DSP). The simulation of PMSM with space vector pulse widths modulation (SVPWM) inverter presented under several operating condition. To verify the simulation results a hard ware setup is prepared and tested at several operating conditions using dspace 1102 DSP model. The experimental and simulation results are in agreement and the torque dynamic response is very rapid and the system achieves the steady state in a very short time.
Giant granular cell tumour of the adult female is an uncommon benign tumour of uncertain origin. The typical clinical appearance is of a single nodule occurring on the left posterior maxillary area . In 10% of cases there are multiple lesions. The occurrence of Giant granular cell tumour in Chinese is rare.
Case situation : One firm pedunculated nodular lesions were noticed ( mass ) in the mouth of a 25-old Chinese female: one on the left posterior maxillary moler +8 area.
Conclusion: Surgical wound healing using electrocautery is faster compared to other techniques, chance giant cell tumor recurrence and Giant granular cell tumour occurs almost exclusively in Chinese newborns but also rarely in adult female. The Patient should be assured of the benign nature and the simple treatment of the condition.
Giant granular cell tumour occurs almost exclusively in Chinese newborns but also rarely in adult female.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.